SCHEMBL21483428

SCHEMBL21483428

CN(C(=O)OC(C)(C)C)C(Cc1ccccc1)C(=O)NC(Cc1ccc(NS(=O)(=O)O)cc1)c1nc(-c2ccccc2)cs1

nearest known ligand 0.75

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
▸ PTPRB P23467 20/20 0.75

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL679361 1.00 PTPRB (0.75) PTPRB
SCHEMBL680221 0.89 PTPRB (0.75) PTPRB
SCHEMBL14648828 0.89 PTPRB (0.75) PTPRB
SCHEMBL28828076 0.87 PTPRB (0.87) PTPRB
SCHEMBL679586 0.87 PTPRB (0.87) PTPRB
SCHEMBL468067 0.86 PTPRB (1.00) PTPRB
SCHEMBL468066 0.86 PTPRB (1.00) PTPRB
SCHEMBL19502577 0.86 PTPRB (0.74) PTPRB
SCHEMBL3579993 0.86 PTPRB (0.74) PTPRB
SCHEMBL679360 0.84 PTPRB (1.00) PTPRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200108080-A1 COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES EyePoint Pharmaceuticals, Inc. 2020-04-09 — — US disclosed
EP-3556367-A1 BENZOSULFONAMIDE DERIVATIVES, COMPOSITIONS THEREOF, AND THEIR USE IN THE TREATMENT OF CANCER OR METASTASIS Aerpio Therapeutics, Inc. (US) 2019-10-23 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200108080-A1 COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES VEGFA, FLT4, AQP3 PTPRB 2215/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback